Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (355)	8/2/2005 12:57:14 AM
From: tuck	Respond to of 510

[HUPO reference specimens and SELDI] >>Proteomics. 2005 Jul 29; [Epub ahead of print] Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers. Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, Podust VN, Patel M, Lim LY, Shipulina NV, Chan DW, Semmes OJ, Eastwood Leung HC. Department of Pathology, Division of Clinical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, USA. We report on a multicenter analysis of HUPO reference specimens using SELDI-TOF MS. Eight sites submitted data obtained from serum and plasma reference specimen analysis. Spectra from five sites passed preliminary quality assurance tests and were subjected to further analysis. Intralaboratory CVs varied from 15 to 43%. A correlation coefficient matrix generated using data from these five sites demonstrated high level of correlation, with values >0.7 on 37 of 42 spectra. More than 50 peaks were differentially present among the various sample types, as observed on three chip surfaces. Additionally, peaks at approximately 9200 and approximately 15 950 m/z were present only in select reference specimens. Chromatographic fractionation using anion-exchange, membrane cutoff, and reverse phase chromatography, was employed for protein purification of the approximately 9200 m/z peak. It was identified as the haptoglobin alpha subunit after peptide mass fingerprinting and high-resolution MS/MS analysis. The differential expression of this protein was confirmed by Western blot analysis. These pilot studies demonstrate the potential of the SELDI platform for reproducible and consistent analysis of serum/plasma across multiple sites and also for targeted biomarker discovery and protein identification. This approach could be exploited for population-based studies in all phases of the HUPO PPP.<< Just got back from vacation, and am catching up. Not sure what to make of the deal yet. I'll comment when I've looked more deeply. Cheers, Tuck

To: nigel bates who wrote (355)	8/3/2005 3:53:12 PM
From: tuck	Read Replies (1) \| Respond to of 510

Things are getting interesting: rumors of substantial restructuring, continued shareholder revolt (follow-up from noise made this February) in the form of no-confidence vote, and possible takeover: finance.messages.yahoo.com and next message. From our old fave GenomeWeb via Yahoo! poster. Stock is trading fairly heavily but steadily. I'm guessing earnings are slightly light, but not so much as to trigger a warning. Interesting quote by someone at Ciphergen saying that Quest feels "burned" by Correlogic. They must have felt that way just recently, because within two months ago they made an equity investment of an undisclosed amount in Correlogic. Cheers, Tuck